ReMDO conducts regenerative medicine research with an ultimate goal to de-risk and accelerate the transition of regenerative medicine technologies to the global market and speed up the translation to clinical practice to help make patients lives better.
The research portfolio is comprised of four programs funded by public-private partnerships between the government, industry, and academic teams.
Universal Bioink Program
The ReMDO Universal Bioink program is developing sets of hydrogels to be used as a tunable bioink that will not need to be designed from scratch, but rather be more like an out-of-the box bioink that could be used across different bioprinting platforms (e.g. extrusion, ink jet, etc.), and compatible with supporting different cell types (e.g. endothelial cells or cardiac cells).
Standardized Cell Culture Media
Standardized cell culture media—liquids that support cell growth.
The overall objective of the media program is to develop a well-defined, xeno-free basal medium that supports the growth and viability of human cells derived from each of the three germ layers, and that can be used in conjunction with three specific supplements, each of which has been optimized to support the expansion of cells. These germ layer-specific formulations will then be augmented with additional factors tailored to support the growth and function of several specific human cell types commonly employed in regenerative medicine. Because all formulations will be derived from the same “universal” basal medium, review by domestic and regulatory agencies will be greatly simplified and manufacturing costs will be substantially lowered.
The Medical Technology Enterprise Consortium (MTEC) is a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) that serves those who serve our nation. In partnership with the Department of Defense and private support, MTEC is working to prevent injuries and accelerate the development of revolutionary medical solutions. ReMDO’s collaboration aims to advance biomedicine and create amazing new possibilities.
The ReMDO Bioreactor Program seeks to develop a universal standardized bioreactor platform for the maturation of regenerative medicine clinical products. The system will be scalable across the clinically relevant range and configurable for clinically relevant construct geometries.
Cell Isolation Program
The ReMDO Cell Isolation Program will combine several cutting-edge cell isolation and purification strategies into an automated system for consistently generating the cell populations. The goal is to develop a standardized and automated platform for isolating highly-defined cell populations from biologically complex human clinical specimens for clinical manufacturing.